^
    Back
    Association details:
    Biomarker:HER-2 1899‐1G>A
    Cancer:Gastric Adenocarcinoma
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    The Oncologist
    Title:

    HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma

    Published date:
    04/25/2021
    Excerpt:
    ...we first report the nucleotide change c.1899‐1G>A at the intron 15 acceptor splice site promoting exon 16 deletion of HER2 as the potential mechanism of trastuzumab resistance in HER2‐positive gastric adenocarcinoma.
    DOI:
    https://doi.org/10.1002/onco.13799